Safety & Tolerance
The ingredients in Holigos™ IBS are generally recognized as safe (GRAS) and have been certified as safe
Holigos™ IBS contains two oligosaccharides naturally found in human milk and both are certified as safe by the European Food Safety Authority (EFSA) and accorded GRAS status by the US Food and Drug Administration (FDA). Both have been approved for use in infant formula and medical foods.
Holigos™ IBS is very well tolerated by infants, children and adults, including IBS patients
Holigos™ has been evaluated in several randomized, placebo controlled clinical trials9,10,11 and has very good tolerance in infants, children and adults (both healthy and IBS patients). In total, over 2000 people have tested Holigos™ during development.
There is no difference in reported adverse events between Holigos™ IBS and placebo
The number of adverse events (AEs) reported in the clinical trials are similar for participants taking Holigos™ or placebo. The most commonly reported AEs are local reactions in the gut, such as abdominal pain, distension and flatulence. All AE were considered to be of mild or moderate severity. No serious adverse events attributed to Holigos™ have been reported and trial discontinuation rates were infrequent and similar between Holigos™ and placebo.
Food allergies and intolerances
- Soy, peanut, egg or gluten: Holigos™ IBS does not contain soy, peanut, egg or gluten
- Lactose: Holigos™ IBS is suitable for consumption by people who are lactose intolerant. Each daily dose of Holigos™ IBS contains less than 0.2g of lactose which is generally too low to trigger symptoms of lactose intolerance. Further, Holigos™ IBS promotes the growth of beneficial bacteria which consume lactose.
- Milk protein: Holigos™ IBS may contain traces of milk protein
Holigos™ IBS may be used during pregnancy and lactation at clinical discretion
Holigos™ IBS has not been tested in pregnant or lactating women. However, Holigos™ IBS contains glycans which are found in high concentrations in mother’s milk and are beneficial to the nursing baby. Therefore, safety and tolerance issues are not expected but the choice to administer Holigos™ IBS during pregnancy or to nursing mothers is at the clinical discretion of the medical professional.
No potential drug interactions have been identified from any source including clinical trials
No interactions trials have been conducted in people who are taking Holigos™ IBS and other medicines. However, no potential drug interactions have been identified from any source including clinical trials.
Read more about clinical evidence